Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Hosted on MSN13h
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, ...
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...
Business Wire21h
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered ...